On July 22, 2025, the FDA announced more details on the CNPV pilot program (here), indicating that the Agency will accept no more than five applications for the first year (2025). The announcement provides a broad program overview along with key program benefits.
The announcement also outlines the eligibility criteria for inclusion, stating:
“Your company must demonstrate alignment with one or more of the Program Priorities above. Please note companies are limited to submitting one application. Vouchers can be granted by the FDA for review of a company’s specific drug or be granted to a company as an undesignated voucher, allowing a company to use the voucher for review of a pre-market application for a drug at the company’s discretion subject to consistency with the program’s objectives.”
Specific program priorities are described as well. These include:
- Addressing a U.S. public health crisis
- Delivering more innovative cures for the American people
- Addressing a large unmet medical need
- Onshoring drug development and manufacturing to advance the health interests of Americans and strengthen U.S. supply chain resiliency
- Increasing affordability
The examples provided relative to each program priority are, in some cases, quite broad (for instance, developing a treatment for “a condition that available therapies do not adequately diagnose or treat, including drugs to treat or prevent rare diseases or addressing America’s chronic disease crisis”) and others are quite specific (for example, “creating a novel immunotherapy that reprograms the body’s immune system to fight multiple diseases; or transforming mental health care through a novel treatment for PTSD”). See more details regarding the program’s priorities at the link above as well as the FAQs, also issued on July 22nd, which provide additional clarity about the program (here). This will be a very interesting program to watch unfold and to see whether its lightning-fast approval target of one to two months is achievable.
